Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Bratisl Lek Listy ; 124(1): 47-52, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-36519607

RESUMO

OBJECTIVES: The purpose of this study is to investigate the effects of cholinergic anti-inflammatory pathway (CAP)-activating drugs, choline and citicoline (Cytidinediphosphate-choline, CDP-choline), on lipopolysaccharide (LPS)-induced acute kidney injury (AKI) parameters and the contribution of NADPH Oxidase4 (NOX4) p22phox. BACKGROUND: Endotoxemia induces a systemic inflammatory response characterized by the production of pro-inflammatory mediators and reactive oxygen species (ROS), which eventually develops acute kidney injury (AKI). NADPH Oxidase4 (NOX4) p22phox pathway contributes to the development of endotoxemia-induced AKI. Inflammatory response can be controlled by CAP. METHODS: Expressions levels of KIM-1, TNF-α, NOX4, p22phox and NFκB in the kidney tissues of rats were analyzed via RT-PCR in experimental groups; 1. Control, 2. LPS (10 mg/kg) + saline, 3. LPS + CDP-choline (375 mg/kg) and 4. LPS + choline (90 mg/kg). Choline and ROS levels in kidney tissues were also measured by a spectrofluorometric assay. RESULTS: LPS-induced elevations of ROS levels were decreased by CDP-choline or choline administration (p < 0.001). LPS-elevated KIM-1, TNFα, NOX4, p22 phox, and NFκB expressions were significantly decreased by choline or CDP-choline treatments (p < 0.001). CONCLUSION: Decreased ROS production in kidney tissues in treatment groups suggests that choline or CDP-choline may have therapeutic potential in endotoxemia-associated AKI via downregulating NOX4 and p22phox expressions (Tab. 1, Fig. 5, Ref. 45). Text in PDF www.elis.sk Keywords: endotoxemia, choline, cytidine diphosphate choline, acute kidney injury, reactive oxygen species.


Assuntos
Injúria Renal Aguda , Endotoxemia , Ratos , Animais , Citidina Difosfato Colina/farmacologia , Citidina Difosfato Colina/uso terapêutico , Citidina Difosfato Colina/metabolismo , Espécies Reativas de Oxigênio/metabolismo , Endotoxemia/tratamento farmacológico , Endotoxemia/metabolismo , Lipopolissacarídeos/farmacologia , Colina/metabolismo , Colina/farmacologia , Colina/uso terapêutico , NADP/metabolismo , NADP/farmacologia , NADP/uso terapêutico , Estresse Oxidativo , Injúria Renal Aguda/tratamento farmacológico , Injúria Renal Aguda/induzido quimicamente , NF-kappa B/metabolismo , Rim
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA